To conclusively demonstrate that the observed increase in sensitivity to anti-PD-L1 immunotherapy induced by 2DG combination is driven by its effect on CD8+ T cells, we conducted an in vivo experiment where we depleted CD8+ T cells using an anti-CD8 antibody in HR-proficient tumor-bearing mice and then treated them with or without the combination of 2DG and anti-PD-L1. The gene discussed is CD8A; the disease is neoplasm.